Cost-Effectiveness of Apixaban Versus Other New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation

Study Questions:

How cost-effective is apixaban compared to dabigatran and rivaroxaban in patients with nonvalvular atrial fibrillation (AF)?